| 1.29 -0.07 (-5.15%) | 07-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Akoya Biosciences, Inc. is a prominent life sciences technology firm dedicated to furnishing advanced spatial biology solutions. The company's mission is to significantly advance both discovery and clinical research across numerous global regions, including North America, Asia Pacific, Europe, the Middle East, and Africa. Their core product lineup features the PhenoCycler instrument, a compact benchtop fluidics system designed to integrate seamlessly with a microscope for automated image acquisition. Complementing this is the PhenoImager platform, which empowers researchers to intricately visualize, analyze, quantify, and characterize cells directly within diverse tissue samples—such as fresh frozen or FFPE sections and tissue microarrays—through an efficient, automated, and high-throughput process. Akoya also supplies the essential reagents for these PhenoCycler and PhenoImager systems, alongside providing specialized biopharmaceutical services. Beyond hardware, Akoya offers a robust suite of software tools. Proxima serves as a cloud-based platform for the secure storage, comprehensive analysis, and collaborative sharing of spatial data. For image interpretation, the inForm Tissue software delivers automated analysis to precisely visualize and quantify biomarkers within tissue sections. Further streamlining data workflows, Phenoptr facilitates the consolidation and in-depth analysis of output tables generated by inForm. Finally, phenoptrReports is a user-friendly software application that generates intuitive reports and visualizations from phenoptr output, presented via an easy-to-navigate graphical user interface. Established in 2015, Akoya Biosciences maintains its corporate headquarters in Marlborough, Massachusetts.
Tue, 01 Sep 2026
icad inc (ICAD) Peer Comparison – Compare with Others - Value Research
Tue, 08 Jul 2025
Quanterix completes acquisition of Akoya Biosciences, delisting set from Nasdaq - Investing.com
Thu, 24 Apr 2025
Akoya BioSciences (AKYA) Stock Price, News & Analysis - Stock Titan
Mon, 14 Apr 2025
Quanterix Faces Investor Backlash: $30M Convertible Notes Deal Under Fire - Stock Titan
Mon, 17 Mar 2025
Akoya BioSciences Inc. (AKYA) reports earnings - qz.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|